Canada Markets close in 2 hrs 57 mins
  • S&P/TSX

    19,690.25
    +70.12 (+0.36%)
     
  • S&P 500

    4,141.15
    -4.04 (-0.10%)
     
  • DOW

    32,818.33
    +14.86 (+0.05%)
     
  • CAD/USD

    0.7779
    +0.0045 (+0.5827%)
     
  • CRUDE OIL

    89.80
    +0.79 (+0.89%)
     
  • BTC-CAD

    30,750.63
    +888.09 (+2.97%)
     
  • CMC Crypto 200

    557.36
    +14.49 (+2.67%)
     
  • GOLD FUTURES

    1,804.00
    +12.80 (+0.71%)
     
  • RUSSELL 2000

    1,935.66
    +13.83 (+0.72%)
     
  • 10-Yr Bond

    2.7660
    -0.0740 (-2.61%)
     
  • NASDAQ

    12,652.58
    -4.98 (-0.04%)
     
  • VOLATILITY

    21.79
    +0.64 (+3.03%)
     
  • FTSE

    7,482.37
    +42.63 (+0.57%)
     
  • NIKKEI 225

    28,249.24
    +73.37 (+0.26%)
     
  • CAD/EUR

    0.7627
    +0.0036 (+0.47%)
     

ProQR to Participate in the Kempen Life Sciences Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
ProQR Therapeutics N.V.
ProQR Therapeutics N.V.

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced that Company management will participate in the Kempen Life Sciences Conference on April 20, 2022.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer®, which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on RNA) to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for genetic diseases. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.

Learn more about ProQR at www.proqr.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our participation in this conference. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

ProQR Therapeutics N.V.

Investor Contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Hans Vitzthum
LifeSci Advisors
T: +1 617 430 7578
hans@lifesciadvisors.com

Media Contact:
Robert Stanislaro
FTI Consulting
T: +1 212 850 5657
robert.stanislaro@fticonsulting.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting